

## Dopamine and antipsychotic drug action revisited

H. M. JONES and L. S. PILOWSKY

The key event in the initiation of pharmacological responses is the formation of a complex between the ligand (or drug or molecule) and its site of action (Taylor & Insel, 1990). Competitive binding experiments ascertain how specific the interaction is between a ligand and its binding site by examining the ability of various compounds to compete with a radiolabelled reference probe for the site. The more potently a drug binds to the receptor, the more effective it is at competing for labelled sites. The greater the potency a drug has for the receptor, the lower the concentration required before all available receptor sites are occupied or blocked. This affinity (termed  $K_d$  or  $K_i$ ) for the receptor is quantified in test-tube experiments and is a function of the rate of drug association and dissociation from the receptor. It is empirically measured as the concentration of drug required to block half the total receptor population. High-affinity drugs have low  $K_d$  values. These drugs are better at ‘occupying’ receptors. In living animals, including humans, receptor occupancy by drugs is also determined by the rate of association and dissociation of the drug from the receptors, the concentration of drug at the receptor and the concentration of endogenous neurotransmitter at the receptor (Strange, 2001). Rehearsing these dry pharmacological concepts is important to our understanding of antipsychotic drug action, in particular how dopamine is the ‘come-back kid’ for hypotheses of antipsychotic drug action, a lead candidate for antipsychotic drug discovery and relevant to the modern clinical management of schizophrenia. Here we shall discuss the dopamine hypothesis of drug action, review studies that have refined understanding of its relevance, and attempt to synthesise the current view with respect to clinical management.

### DOPAMINERGIC PATHWAYS AND RECEPTOR PHYSIOLOGY

Dopamine is one of the principal modulatory neurotransmitters in the brain. Dopamine systems arise from two primary midbrain clusters, the ventral tegmental area (A10) and the substantia nigra (A9), which have discrete projections to mesolimbic, mesocortical and striatal regions of the brain. A separate tuberoinfundibular pathway runs from hypothalamic neurons to the pituitary gland. The dopamine receptor family separates into two major subtypes: D<sub>1</sub>-like (D<sub>1</sub> and D<sub>5</sub>) and D<sub>2</sub>-like (D<sub>2</sub>, D<sub>3</sub>, D<sub>4</sub>). Variants of the dopamine receptors exist with different DNA and amino acid sequences. Receptor cloning has identified two isoforms of the D<sub>2</sub> receptor (D<sub>2short</sub> and D<sub>2long</sub>), which are differentially localised in the brain. The neurochemical anatomy of dopamine differs in cortical and striatal regions, and it now appears that dopamine concentration, receptor regulation and D<sub>2</sub>-like receptor subtype density vary greatly between striatal and extrastriatal regions (Lidow *et al*, 1998; Strange, 2001). Antipsychotic drugs are thought to achieve their main effects (both beneficial and unwanted) by acting on D<sub>2</sub> receptors.

### DOPAMINE RECEPTORS AND ANTIPSYCHOTIC DRUG ACTION

#### The D<sub>2</sub> receptor blockade hypothesis

Without exception, effective antipsychotic drugs have at least some degree of antagonism of the dopamine D<sub>2</sub> receptors. The observation that antipsychotic drug affinity for the D<sub>2</sub> receptor and the average daily dose required to control symptoms were directly correlated (Peroutka & Snyder, 1980) led to confirmation that it was a major site of action of antipsychotic drugs

(Creese *et al*, 1976; Seeman *et al*, 1976; Johnstone *et al*, 1978). These findings rationalised clinical observation and practice at the time. Efforts to treat partially or poorly responsive patients revolved around ‘mega-dose’ antipsychotic therapy, although many contemporaneous papers questioned the usefulness of this approach (Baldessarini *et al*, 1984; Van Putten & Marder, 1986). More D<sub>2</sub> receptor blockade was better, the theory went, and concomitant movement disorder (secondary to striatal D<sub>2</sub> receptor blockade) and hyperprolactinaemia (secondary to pituitary D<sub>2</sub> blockade) were an inevitable, if unfortunate, corollary of treatment.

#### Re-evaluation of the dopamine hypothesis of antipsychotic drug action

In the 1980s and 1990s the simple understanding that dopamine D<sub>2</sub> receptor blockade was linearly related to clinical response was reversed (as is so often the case in schizophrenia research) by powerful new research tools, which forced the re-evaluation of the role of D<sub>2</sub> receptors in antipsychotic drug action. These included receptor imaging *in vivo* with positron and single photon emission tomography (PET and SPET). One PET study showed that up to 12 different typical antipsychotic drugs had 65–85% occupancy at D<sub>2</sub> receptors in living patients (Farde *et al*, 1989). Subsequent studies revealed that the degree of D<sub>2</sub> receptor occupancy was directly correlated with the dose (or plasma level) of traditional antipsychotic drugs; but did D<sub>2</sub> receptor occupancy also correlate with clinical benefit?

Chinks in the ‘dopamine hypothesis’ armour appeared with the clear demonstration that some patients taking therapeutic doses of typical antipsychotic drugs not only failed to benefit from the treatment, but also had levels of central D<sub>2</sub> receptor blockade in excess of 90% (Wolkin *et al*, 1989; Pilowsky *et al*, 1993). This finding obviated pharmacokinetic explanations that poor clinical effect was the result of low brain penetration or increased wash-out of typical antipsychotic drugs in treatment-resistant individuals. Indeed, some patients who responded well to treatment showed remarkably low levels of D<sub>2</sub> receptor blockade (Pilowsky *et al*, 1993). These data contributed greatly to the consensus that high-dosage antipsychotic treatment was,

in the main, unhelpful in the treatment of poorly responsive schizophrenia (Thompson, 1994). Finally, clozapine, a therapeutically superior antipsychotic drug without extrapyramidal side-effects (and modest affinity for D<sub>2</sub> receptors *in vitro*) had consistently low levels of D<sub>2</sub> receptor blockade (ranging from 20% to 60%) in association with excellent clinical response, even in patients previously poorly responsive to standard or high-dosage typical antipsychotic drug therapy (Pilowsky *et al*, 1992).

This evidence prompted a careful re-interpretation of the importance of D<sub>2</sub> receptor blockade to therapeutic efficacy. Other receptor systems were probed as potential sites of antipsychotic drug action, and a call was made to abandon preconceived ideas of particular neurochemical profiles determining atypical drug activity until potential sites for drug discovery were better understood (Kerwin, 1994). Simple behavioural or clinical definitions of atypicality (low or no extrapyramidal symptoms or hyperprolactinaemia at therapeutically relevant doses) would preserve an open field for novel therapeutic targets. Most notable of these was the 5-hydroxytryptamine type 2 (5-HT<sub>2</sub>) receptor subclass. Meltzer *et al* (1989) proposed, on the basis of drug affinity data, that the ratio of 5-HT<sub>2A</sub> to D<sub>2</sub> receptor affinities was the major determinant of a drug's likelihood to behave as an atypical antipsychotic. Studies using PET and SPET found that many atypical antipsychotic drugs, including clozapine, olanzapine, risperidone and quetiapine, shared a strikingly high degree of 5-HT<sub>2A</sub> receptor occupancy (>90%) over their entire dose range (Nordstrom *et al*, 1993a; Nyberg *et al*, 1993; Travis *et al*, 1998; Kapur *et al*, 1999; Jones *et al*, 2001). This is unsurprising given that olanzapine, risperidone and quetiapine were developed on the basis of their high 5-HT<sub>2A</sub>:D<sub>2</sub> receptor affinity profiles. It appears from the results of further studies (particularly the failure of pure 5-HT<sub>2A</sub> antagonists to show striking therapeutic effects) that 5-HT<sub>2A</sub> receptor occupancy alone is unlikely to be sufficient to determine clinical efficacy for antipsychotic drugs (Kapur *et al*, 1999).

### The central primacy of dopamine to antipsychotic action

The notion that D<sub>2</sub> receptor occupancy was central to therapeutic response never really went away. Compounds that lack

even modest activity at these sites are therapeutically inactive. Nordstrom *et al* (1993b) and later Kapur *et al* (2000a) showed that symptom reduction and side-effect induction could be fitted to a threshold model of striatal D<sub>2</sub> receptor occupancy (at least in acutely relapsed patients and excluding excellent responders and treatment-resistant cases). In one study of 22 patients (5 women and 17 men) with first-episode schizophrenia, Kapur *et al* (2000a) demonstrated that striatal D<sub>2</sub> receptor occupancy values exceeding approximately 65% predicted clinical benefit, values exceeding 72% predicted hyperprolactinaemia, and values exceeding 78% predicted motor side-effects. For the clinician, maintaining patients within a therapeutic window of 7–15% D<sub>2</sub> receptor occupancy is not straightforward, especially when prescribing haloperidol, since doses as low as 2.5 mg of this drug result in a wide variation in striatal D<sub>2</sub>/D<sub>3</sub> receptor occupancy (38–87%).

Furthermore, individual responses to similar degrees of D<sub>2</sub> receptor occupancy may vary, based on other as yet undefined pharmacogenetic characteristics and on the individual's underlying dopaminergic tone (Laruelle *et al*, 1996). It is pertinent to this point that hyperprolactinaemia occurred in 80% (4 out of 5) of the women and 24% (4 out of 17) of the men in the study by Kapur *et al* (2000a) despite similar levels of D<sub>2</sub> receptor occupancy. Melkersson *et al* (2000) reported that in a group of patients receiving long-term typical antipsychotic therapy, the women developed symptomatic hyperprolactinaemia at half the chlorpromazine equivalent dose of that in men (approximately 250 mg chlorpromazine equivalents).

### Dopamine transmission is abnormal in schizophrenia

Post-mortem studies of D<sub>2</sub> receptors in schizophrenia were crucial to the genesis of the dopamine hypothesis. Increased striatal D<sub>2</sub> receptor density was reported by some authors (Lee & Seeman, 1980; Mackay *et al*, 1982), but these findings were questioned on the basis that the data were obtained by studying antipsychotic-treated patients. Classical antipsychotic therapy could, in itself, cause D<sub>2</sub> receptor upregulation (Clow *et al*, 1980). Imaging studies using PET and SPET could control for this confound by studying never-treated people with schizophrenia. These studies

did not, on the whole, support increased striatal D<sub>2</sub> receptor density in schizophrenia (Farde *et al*, 1990; Martinot *et al*, 1990; Pilowsky *et al*, 1994), although the possibility that endogenous dopamine concentration was abnormal (Mackay *et al*, 1982; Reynolds, 1983) remained untested *in vivo*. Support for the central importance of dopaminergic antagonism in antipsychotic efficacy eventually came from [<sup>123</sup>I]-iodobenzamide SPET data suggesting that dopamine transmission was indeed disrupted in schizophrenia. Using dynamic challenge paradigms, Laruelle *et al* (1996) demonstrated an aberrant response in people with schizophrenia to a drug that elevated dopamine levels. Following administration of amphetamine, mean occupancy of striatal D<sub>2</sub> receptors by amphetamine-stimulated endogenous dopamine release was approximately doubled in the patient group compared with the control group. This effect was more striking in the more acutely ill patients, although findings in many patients overlapped with those in controls. These data, replicated using a different PET technique (Breier *et al*, 1997), provided concrete proof of disturbed dopamine control, at least in some people with schizophrenia. Drawing on these and other data, Moore *et al* (1999) have thoughtfully argued that overactive phasic dopamine transmission in limbic regions (including the amygdala and nucleus accumbens) could account for misinterpretation of innocuous external stimuli (resulting in delusions) and improper filtering of perceptions (causing hallucinations). Blockade of D<sub>2</sub> receptors in these regions would help control the positive symptoms of schizophrenia. In cortical (especially frontal and prefrontal cortical) regions, these authors propose that tonic dopamine transmission is relatively underactive, resulting in disrupted executive function, poverty of thought, speech and action, and low motivation. Antipsychotic occupancy of D<sub>2</sub> receptors in these regions would worsen these negative features. This attractively parsimonious model synthesises available data and meshes with the finding that atypical antipsychotic drugs (particularly clozapine and quetiapine) exhibit cortically selective D<sub>2</sub> receptor occupancy (primarily temporal cortex, including amygdala and hippocampus) at clinically useful doses *in vivo* (Pilowsky *et al*, 1997; Lidow *et al*, 1998; Meltzer *et al*, 1999; Stephenson *et al*, 2000; Xiberas *et al*, 2001). This effect is not seen for standard

doses of typical antipsychotic drugs (Bigliani *et al*, 1999). Importantly, drugs with modest affinity for D<sub>2</sub> receptors exhibit this effect robustly across their whole dose range, whereas atypical drugs with higher affinity for the D<sub>2</sub> receptor (e.g. risperidone) display dose-dependent limbic selectivity (Xiberas *et al*, 2001; Bressan *et al*, 2003; Fig. 1).

These data could not be replicated by Talvik *et al* (2001), and full *in vivo* PET or SPET confirmation awaits further study. Nevertheless, regionally selective dopaminergic action of atypical antipsychotic drugs is supported by both electrophysiological and animal studies (Lidow *et al*, 1998; Strange, 2001).

### How much D<sub>2</sub> blockade is too much?


The advent of antipsychotic drugs with very low affinity for dopamine D<sub>2</sub> receptors

(most notably clozapine and quetiapine) begged the question whether D<sub>2</sub> receptor blockade was invariably required for antipsychotic efficacy. Imaging studies using PET reveal that striatal D<sub>2</sub> receptor occupancy by these drugs changes considerably over a 24 h period, even in steady state (Gefvert *et al*, 1998; Kapur *et al*, 2000b). Consideration of the D<sub>2</sub> receptor affinity and occupancy data relating to typical and atypical antipsychotic drugs led Kapur & Seeman (2001) to conclude that owing to low affinity for the D<sub>2</sub> receptor (driven, as these authors see it, by fast dissociation 'off' the receptor) clozapine and quetiapine exhibit transiently high D<sub>2</sub> receptor occupancy (not exceeding the threshold required to induce adverse movement or hormonal side-effects), which declines to very low levels over a 24 h period. This suggests that low-affinity drugs, with modest effects at D<sub>2</sub> receptors, may antagonise the system in a manner that preserves physiologically

responsive endogenous dopamine transmission across a wide dose range (Kapur *et al*, 2000b). The effect may presumably also be achieved by higher-affinity drugs that are cleared rapidly from the synapse, or given at doses producing low synaptic concentrations of the drug (Strange, 2001). These data still do not explain the well-documented discrepancy between the rapid D<sub>2</sub> receptor blockade induced by antipsychotic drugs and the gradual remission of psychotic symptoms over several days or weeks. This delay could result from longer-term effects of antipsychotic drugs on brain plasticity, including (for example) synaptogenesis (Konradi & Heckers, 2001).

### TO AFFINITY. . . AND BEYOND! 'SMART' ANTIPSYCHOTIC DRUGS

The above suggests that a reasonable goal for effective, less-toxic treatment of schizophrenia is the regionally sensitive stabilisation of dopamine function, and not the 'blunderbuss' dopaminergic paralysis induced by classical antipsychotic drugs. This selective targeting could come about by exploiting behaviour intrinsic to compounds with low D<sub>2</sub> affinity, by designing compounds selective for dopamine receptor subtypes found at greater densities in limbic or cortical regions (for example D<sub>3</sub> receptors), or by modulating dopamine release through action at alternative systems (novel candidates include serotonin, sigma and glutamate receptor sites). Such ideas are certainly relevant to current therapeutics and future drug development. Novel agents with specific action at presynaptic D<sub>3</sub> autoreceptors controlling central dopamine release may offer more physiological modulation of dopamine than conventional antagonists (Reavill *et al*, 2000; Strange, 2001). It is apparent that as the neurochemical pathology of schizophrenia is not fully understood, and as many patients are only partially responsive or are insensitive to dopaminergic antagonism, many non-dopaminergic sites (especially those mediated by glutamate and serotonin) remain potent targets for future drug discovery. The availability of high- and low-affinity D<sub>2</sub>/D<sub>3</sub> receptor antagonist antipsychotic drugs offers clinicians much choice, and the above data provide a rational evidence base for prescribing,



**Fig. 1** Preferentially high occupancy of dopamine D<sub>2</sub>/D<sub>3</sub> receptors in the thalamus and temporal cortex by risperidone in a patient treated with risperidone (dose < 4 mg) compared with a healthy volunteer (see Bressan *et al*, 2003). (a, b) Normal volunteer: (a) striatum and thalamus, (b) temporal cortex and cerebellum. (c, d) Patient treated with risperidone: (c) striatum and thalamus, (d) temporal cortex and cerebellum.

tailored as far as possible to individual patient responses.

## DECLARATION OF INTEREST

H.M.J. is supported by an unrestricted charitable grant from Astrazeneca. L.S.P. is a UK Medical Research Council Senior Clinical Fellow and has received research grants from Astrazeneca, Novartis, Janssen and Sanofi-Synthelabo, and honoraria for lectures and consultancies to GlaxoSmith Kline, Astrazeneca, Novartis, Pfizer and Janssen.

## REFERENCES

- Baldessarini, R. J., Katz, B. & Cotton, P. (1984)** Dissimilar dosing with high and low potency neuroleptics. *American Journal of Psychiatry*, **141**, 748–752.
- Bigliani, V., Mulligan, R. S., Acton, P. D., et al (1999)** *In vivo* occupancy of striatal and temporal cortical D<sub>2</sub>/D<sub>3</sub> dopamine receptors by typical antipsychotic drugs. [<sup>123</sup>I] epidepride single photon emission tomography (SPET) study. *British Journal of Psychiatry*, **175**, 231–238.
- Breier, A., Su, T. P., Saunders, R., et al (1997)** Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. *Proceedings of the National Academy of Sciences of the USA*, **94**, 2569–2574.
- Bressan, R. A., Erlundsson, K., Jones, H. M., et al (2003)** Optimising limbic selective D<sub>2</sub>/D<sub>3</sub> receptor occupancy by risperidone – a 123I epidepride SPET study. *Journal of Clinical Psychopharmacology*, in press.
- Clow, A., Theodorou, A., Jenner, P., et al (1980)** Changes in rat striatal dopamine turnover and receptor activity during one year's neuroleptic administration. *European Journal of Pharmacology*, **63**, 135–144.
- Creese, I., Burt, D. R. & Snyder, S. H. (1976)** Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. *Science*, **192**, 481–483.
- Farde, L., Wiesel, F. A., Nordstrom, A. L., et al (1989)** D<sub>1</sub>- and D<sub>2</sub>-Dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. *Psychopharmacology*, **99**, S28–S31.
- , —, Stone-Elander, S., et al (1990) D<sub>2</sub> dopamine receptors in neuroleptic-naïve schizophrenic patients. A positron emission tomography study with [<sup>11</sup>C] raclopride. *Archives of General Psychiatry*, **47**, 213–219.
- Gefvert, O., Bergstrom, M., Langstrom, B., et al (1998)** Time course of central nervous dopamine-D<sub>2</sub> and 5-HT<sub>2</sub> receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. *Psychopharmacology (Berlin)*, **135**, 119–126.
- Johnstone, E. C., Crow, T. J., Frith, C. D., et al (1978)** Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. *Lancet*, *i*, 848–851.
- Jones, H., Travis, M. J., Mulligan, R. S., et al (2001)** *In vivo* 5HT<sub>2a</sub> receptor blockade by quetiapine. An R91150 single photon emission tomography study. *Psychopharmacology (Berlin)*, **157**, 60–66.
- Kapur, S. & Seeman, P. (2001)** Does fast dissociation from the dopamine D<sub>2</sub> receptor explain the action of atypical antipsychotics? A new hypothesis. *American Journal of Psychiatry*, **158**, 360–369.
- , Zipursky, R. & Remington, G. (1999) Clinical and theoretical implications of 5-HT<sub>2</sub> and D<sub>2</sub> receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. *American Journal of Psychiatry*, **156**, 286–293.
- , —, Jones, C., et al (2000a) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. *American Journal of Psychiatry*, **157**, 514–520.
- , —, —, et al (2000b) A positron emission tomography study of quetiapine in schizophrenia. *Archives of General Psychiatry*, **57**, 553–559.
- Kerwin, R. W. (1994)** The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research. *British Journal of Psychiatry*, **164**, 141–148.
- Konradi, C. & Heckers, S. (2001)** Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. *Biological Psychiatry*, **50**, 729–742.
- Laruelle, M., Abi-Dargham, A., Van-Dyck, C. H., et al (1996)** Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. *Proceedings of the National Academy of Sciences of the USA*, **93**, 9235–9240.
- Lee, T. & Seeman, P. (1980)** Elevation of brain neuroleptic/dopamine receptors in schizophrenia. *American Journal of Psychiatry*, **137**, 191–197.
- Lidow, M. S., Williams, G. V. & Goldman-Rakic, P. S. (1998)** The cerebral cortex: a case for a common site of action of antipsychotics. *Trends in Pharmacological Sciences*, **19**, 136–140.
- Mackay, A. V., Iversen, L. L., Rossor, M., et al (1982)** Increased brain dopamine and dopamine receptors in schizophrenia. *Archives of General Psychiatry*, **39**, 991–997.
- Martinot, J. L., Peron-Magnan, P., Huret, J. D., et al (1990)** Striatal D<sub>2</sub> dopaminergic receptors assessed with positron emission tomography and <sup>76</sup>Br bromospiperone in untreated schizophrenic patients. *American Journal of Psychiatry*, **147**, 44–50.
- Melkersson, K. I., Hulting, A. L., Rane, A. J. (2000)** Dose requirement and prolactin elevation of atypical antipsychotics in male and female patients with schizophrenia or related psychoses. *British Journal of Clinical Pharmacology*, **51**, 317–324.
- Meltzer, H. Y., Matsubara, S. & Lee, J. C. (1989)** The ratios of serotonin and dopamine<sub>2</sub> affinities differentiate atypical and typical antipsychotic drugs. *Psychopharmacology Bulletin*, **25**, 390–397.
- , Park, S. & Kessler, R. (1999) Cognition, schizophrenia and the atypical antipsychotic drugs. *Proceedings of the National Academy of Sciences of the USA*, **96**, 13 591–13 593.
- Moore, H., West, A. R. & Grace, A. A. (1999)** The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia. *Biological Psychiatry*, **46**, 40–55.
- Nordstrom, A. L., Farde, L. & Halldin, C. (1993a)** High 5HT<sub>2</sub> receptor occupancy in clozapine treated patients demonstrated by PET. *Psychopharmacology*, **110**, 365–367.
- , —, Weisel, F. A., et al (1993b) Central D<sub>2</sub> dopamine receptor occupancy in relation to antipsychotic drug effects: a double blind PET study of schizophrenic patients. *Biological Psychiatry*, **33**, 227–235.
- Nyberg, S., Farde, L., Eriksson, L., et al (1993)** 5HT<sub>2</sub> and D<sub>2</sub> dopamine receptor occupancy by risperidone in the living human brain. *Psychopharmacology*, **110**, 265–272.
- Peroutka, S. J. & Snyder, S. H. (1980)** Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic and histaminergic receptors to clinical potency. *American Journal of Psychiatry*, **137**, 1518–1522.
- Pilowsky, L. S., Costa, D. C., Ell, P. J., et al (1992)** Clozapine, single photon emission tomography and the D<sub>2</sub> dopamine receptor blockade hypothesis of schizophrenia. *Lancet*, **340**, 199–202.
- , —, —, et al (1993) Antipsychotic medication, D<sub>2</sub> dopamine receptor blockade and clinical response – a 123I IBZM SPET (single photon emission tomography) study. *Psychological Medicine*, **23**, 791–799.
- , —, —, et al (1994) D<sub>2</sub> dopamine receptor binding in the basal ganglia of antipsychotic free schizophrenic patients. An <sup>123</sup>I-IBZM single photon emission computerised tomography study. *British Journal of Psychiatry*, **164**, 16–26.
- , Mulligan, R. S., Acton, P. D., et al (1997) Limbic selectivity of clozapine. *Lancet*, **350**, 490–491.
- Reavill, C., Taylor, S. G., Wood, M. D., et al (2000)** Pharmacological actions of a novel high-affinity, and selective human dopamine D<sub>2</sub> receptor antagonist, SB-277011-A. *Journal of Pharmacology and Experimental Therapeutics*, **294**, 1154–1165.
- Reynolds, G. P. (1983)** Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. *Nature*, **304**, 527–528.
- Seeman, P., Lee, T., Chau-Wong, M., et al (1976)** Antipsychotic drug doses and neuroleptic/dopamine receptors. *Nature*, **261**, 717–718.
- Stephenson, C. M. E., Bigliani, V., Jones, H. M., et al (2000)** Striatal and extra-striatal D<sub>2</sub>/D<sub>3</sub> receptor occupancy by quetiapine *in vivo*. [<sup>123</sup>I]-epidepride single photon emission tomography (SPET) study. *British Journal of Psychiatry*, **177**, 408–415.
- Strange, P. G. (2001)** Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. *Pharmacological Reviews*, **53**, 119–133.
- Talvik, M., Nordstrom, A. L., Nyberg, S., et al (2001)** No support for regional selectivity in clozapine treated patients: a PET study with [<sup>11</sup>C] raclopride and

H. M. JONES, MRCPsych, L. S. PILOWSKY, MRCPsych, Institute of Psychiatry, London, UK

Correspondence: Dr L. S. Pilowsky, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK. Tel: 0207 848 0531 ; e-mail: l.pilowsky@iop.kcl.ac.uk

(First received 3 December 2001, final revision 15 April 2002, accepted 15 April 2002)

[<sup>14</sup>C] FLB 457. *American Journal of Psychiatry*, **158**, 926–930.

**Taylor, P. & Insel, P. A. (1990)** The molecular basis of pharmacologic selectivity. In *Principles of Drug Action – The Basis of Pharmacology* (eds W. B. Pratt & P. Taylor), pp. 1–102. London: Churchill Livingstone.

**Thompson, C. (1994)** The use of high-dose antipsychotic medication. *British Journal of Psychiatry*, **164**, 448–458.

**Travis, M. J., Busatto, G. F., Pilowsky, L. S., et al (1998)** 5HT<sub>2a</sub> receptor blockade in schizophrenic patients treated with risperidone or clozapine, a <sup>123</sup>I-5-I-R-91150 single photon emission tomography (SPET) study. *British Journal of Psychiatry*, **173**, 236–241.

**Van Putten, T. & Marder, S. (1986)** Low dose treatment strategies. *Journal of Clinical Psychiatry*, **47** (suppl. 12), 1–6.

**Wolkin, A., Barouche, F., Wolf, A. P., et al (1989)** Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. *American Journal of Psychiatry*, **146**, 905–908.

**Xiberas, X., Martinot, J. L., Mallet, L., et al (2001)** Extrastriatal and striatal D<sub>2</sub> dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. *British Journal of Psychiatry*, **179**, 503–508.